Welcome to our dedicated page for SQL news (Ticker: SQL), a resource for investors and traders seeking the latest updates and insights on SQL stock.
SQL (SeqLL, LLC) delivers cutting-edge innovations in true single molecule sequencing and strategic workforce solutions. This news hub provides investors and research professionals with timely updates on SQL's dual expertise in high-fidelity genetic analysis and operational support services.
Access comprehensive coverage of SQL's advancements in Helicos SMS technology, including RNA/DNA research breakthroughs and instrumentation developments. Track strategic staffing initiatives addressing talent needs in biotechnology and pharmaceutical sectors. All press releases and news articles are verified for accuracy and relevance.
Key updates include earnings reports, technology partnerships, service expansions, and workforce solution deployments. Bookmark this page for centralized access to SQL's operational milestones and scientific achievements. Return regularly to stay informed about developments impacting life sciences research and biotech operations.
Atlantic International Corp. (OTC: ATLN), formerly known as SeqLL Inc. (OTC: SQL), has announced the acquisition of Lyneer Staffing Solutions. This strategic move creates a national staffing and workforce solutions company with annual revenues exceeding $400 million and an adjusted EBITDA of $5.4 million as of December 31, 2023. The acquisition involves a $35 million promissory note and $60 million in restricted stock. Lyneer serves over 1,100 customers, including major companies like UPS, DHL, FedEx, and PepsiCo. The CEO of Atlantic, Jeffrey Jagid, aims to leverage this acquisition for strategic growth, focusing on medical, IT, and engineering staffing. Additionally, Prateek Gattani of IDC Technologies, the principal shareholder, has been appointed Chairman. The company aims to uplist to a National Securities Exchange soon.
SeqLL Inc. (NASDAQ: SQL; SQLLW) reported its financial results for the year ended December 31, 2022, indicating total revenues of $0.079 million, down 63% from $0.21 million in 2021. Gross profits also decreased by 49%, totaling $0.078 million. Research and development expenses surged 196% to $1.57 million, reflecting a return to pre-pandemic activity levels. General and administrative expenses rose 15% to $2.5 million. The net loss for the year increased by 11% to $4.09 million. Cash, cash equivalents, and investments amounted to $6.2 million as of year-end.
SeqLL Inc. (Nasdaq: SQL, SQLLW) has successfully completed a registered direct offering of 2,000,000 shares of common stock at $0.90 per share, raising approximately $1.8 million in gross proceeds. The offering, facilitated by Maxim Group LLC, is part of the company's ongoing strategy to enhance its life sciences instrumentation and research services. The shares were issued under the company's shelf registration statement filed with the SEC. This financing will support SeqLL's development of its True Single Molecule Sequencing platform, aimed at advancing genomic medicine.
SeqLL Inc. (NASDAQ: SQL, SQLLW) announced a securities purchase agreement with institutional investors to sell 2,000,000 shares of common stock at $0.90 per share in a registered direct offering, generating approximately $1.8 million in gross proceeds. The offering is managed by Maxim Group LLC and is expected to close by February 15, 2023, subject to customary conditions. The shares are being offered under a shelf registration statement declared effective by the SEC. SeqLL specializes in life sciences instrumentation and research services, focusing on the development of innovative solutions in genomics.
SeqLL Inc. (NASDAQ: SQL) has entered a two-year Cooperative Research and Development Agreement (CRADA) with the FBI’s Laboratory Division. The collaboration aims to evaluate forensic capabilities of direct RNA sequencing using SeqLL’s True Single Molecule Sequencing (tSMS®) platform. This partnership will work towards a body fluid identification assay that complements traditional DNA analysis. The agreement is notable as it marks one of the first instances of the FBI using CRADA to enhance laboratory capabilities. SeqLL's CEO expressed optimism about developing forensic applications using their technology.
